Insider Buying as Jason Raleigh Nunn Acquires ZBIO Shares
Jason Raleigh Nunn and other insiders purchased shares of ZBIO on June 15, 2026.
Key Points
- Jason Raleigh Nunn purchased 18,500 shares of ZBIO on June 15, 2026, without a specified price or value.
- ZBIO shares are trading at $18.58, with peer funds like FMR LLC increasing their holdings significantly.
- Analysts maintained various ratings, with price targets ranging from $19 to $55 as of recent updates.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Jason Raleigh Nunn recently purchased 18,500 shares of ZBIO on June 15, 2026. The transaction didn't specify a price or total value, but it's part of a series of insider buys on the same day, indicating a possible positive sentiment among the company's leadership.
Other Institutional Activity in ZBIO
FMR LLC increased its position in ZBIO by 1,377,745 shares, bringing its total to 9,082,000 shares worth about $177.6 million. Meanwhile, NEA Management Company, LLC also boosted its holdings by 500,000 shares, ending with 4,023,219 shares valued at approximately $78.7 million. Federated Hermes, Inc. added 411,453 shares, reaching a total of 3,127,031 shares worth $61.1 million. In contrast, SR One Capital Management, LP and Enavate Sciences GP, LLC maintained their positions without change.
Zenas BioPharma, Inc. Stock Down 40.6%
Shares of ZBIO are trading at $18.58. The stock has seen varied interest from institutional investors, as reflected in recent buying activities. The company's market dynamics and insider transactions could influence its future performance.
Insider Buying and Selling at Zenas BioPharma, Inc.
On June 15, 2026, multiple insiders, including Nunn Jason Raleigh, Boylan James, and Allen Patricia, each purchased 18,500 shares. Joseph Farmer, President and COO, acquired 175,000 shares, while Lisa Von Moltke, Head of Research and Development, bought 150,000 shares. Jennifer Fox, Chief Business Officer and CFO, purchased 125,000 shares. None of these transactions were planned trades under a Rule 10b5-1 plan.
Analysts Set New Price Targets
On May 14, 2026, Morgan Stanley maintained its hold rating on ZBIO with a $22 price target. Earlier, on March 17, Citigroup and Guggenheim reiterated their buy ratings with targets of $41 and $55, respectively. The consensus among analysts suggests a mixed outlook, with a range of price targets indicating potential volatility.
Bottom Line
The recent insider buying activity at ZBIO, including Jason Raleigh Nunn's acquisition, shows significant interest from the company's leadership. While these transactions suggest confidence, they are not definitive indicators of future stock performance. Investors often watch such insider moves closely, but it's important to remember that these are backward-looking reports and may not reflect the current situation.
Get Zenas BioPharma, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ZBIO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.